Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document deployment administration change control and validation support while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
21 CFR Part 11
Part 11 sets criteria under which FDA considers electronic records and signatures trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. Laboratory buyers need to connect system features to the actual electronic records, signatures, controls, and predicate-rule obligations in scope rather than treating a product label as a compliance conclusion.
21 CFR Part 58
Part 58 establishes organizational, personnel, facility, equipment, protocol, operating-procedure, record, reporting, and archive requirements for specified nonclinical studies. Research-system evaluations should trace study, specimen, protocol, instrument, observation, amendment, report, and archive records without assuming an ELN or LIMS alone constitutes a GLP system.
FDA Part 11 Scope Guidance
The guidance explains FDA's narrow interpretation of Part 11 scope and enforcement discretion for certain provisions while retaining applicable predicate-rule requirements. It requires buyers to identify the authoritative record, reliance on the electronic record, predicate rule, copies, retention, and controls before converting a feature checklist into a regulatory assertion.
FDA Computer Software Assurance Guidance
The guidance describes a risk-based approach to establishing confidence in automation used for production or quality systems, including intended use, risk analysis, assurance activities, records, and appropriate testing. It gives laboratory and quality buyers a disciplined way to separate vendor evidence, configured intended use, process risk, assurance activity, unscripted testing, and retained objective evidence.
EU GMP Annex 11
Annex 11 addresses risk management, personnel, suppliers, validation, data, accuracy checks, storage, printouts, audit trails, change, security, incident management, signatures, business continuity, and archiving. It keeps laboratory-system assurance connected to the full system lifecycle and regulated process, not merely a list of application functions.
EU GMP Chapter 4
Chapter 4 places specifications, instructions, procedures, records, reports, controls, approval, availability, legibility, traceability, correction, retention, and hybrid-system relationships within the pharmaceutical quality system. Laboratory architecture should show which system owns each instruction, specification, raw record, result, review, approval, exception, and retained copy across electronic and paper processes.
MHRA Data Integrity Guidance
The MHRA record addresses data governance, lifecycle, criticality, metadata, audit trails, access, review, retention, hybrid systems, and organizational culture. It supports a system-of-record map that follows data from creation through processing, review, reporting, transfer, archive, and destruction while preserving organizational accountability.
PIC/S PI 041-1
PI 041-1 describes data governance, risk, lifecycle, organizational controls, computerized and paper systems, audit trails, review, outsourcing, and remediation considerations. It helps buyers examine data ownership, criticality, system boundaries, third parties, review, backup, archive, and remediation across the laboratory stack.
OECD GLP Principles
OECD GLP principles organize test-facility management, quality assurance, facilities, apparatus, test systems, materials, procedures, study performance, reporting, and archives. Scientific systems should preserve study responsibilities, test-system identity, methods, observations, changes, reports, and archives without conflating system capability with study validity.
OECD GLP Advisory Document No. 22
The advisory document addresses data governance, lifecycle, criticality, metadata, computerized systems, dynamic data, cloud and service arrangements, review, archive, and reconstruction in GLP settings. It supports deeper evaluation of whether a laboratory architecture retains enough context and metadata to reconstruct activity across instruments, analytical systems, scientific repositories, and study records.
ISO 9001:2015
ISO 9001 specifies requirements for a quality management system covering context, leadership, planning, support, operation, performance evaluation, and improvement. Laboratory systems can support controlled operational records and evidence, but the quality system spans leadership, competence, risk, suppliers, process performance, nonconformity, and improvement.
NIST RDaF 2.0
RDaF organizes research-data concerns across planning, lifecycle, infrastructure, standards, governance, workforce, and community perspectives. It gives R&D buyers a broader research-data operating model for stewardship, interoperability, access, preservation, reuse, and governance beyond notebook authoring or file storage.
SiLA 2
SiLA 2 defines service-oriented communication concepts for integrating laboratory devices and software, including feature definitions and a communication protocol. It gives automation buyers a consistent way to examine device capabilities, drivers, interfaces, discovery, commands, properties, metadata, and orchestration boundaries.
NIH DMS Policy
The policy requires applicable researchers to plan for management and sharing of scientific data and to comply with approved plans, subject to limitations and protections. R&D platforms should make data identification, metadata, access, repository, retention, sharing, privacy, and stewardship responsibilities visible without implying that an ELN alone satisfies the plan.
Operating domains
Electronic records and data integrity
The governance and control system for attributable, legible, contemporaneous, original or verified-copy, accurate, complete, consistent, enduring, available records and their metadata throughout the lifecycle.
Scientific data lifecycle and provenance
The architecture for retaining the identity, source, context, transformations, relationships, versions, ownership, access, preservation, and reuse conditions of scientific data and files.
System integration, master data, and interoperability
The operating model for authoritative identities, reference data, transactions, scientific objects, events, documents, error handling, reconciliation, and ownership across laboratory and enterprise systems.
Computerized-system lifecycle, assurance, and change
The managed lifecycle from intended use and process ownership through supplier assessment, risk analysis, configuration, testing, release, operation, access, incident, change, continuity, retirement, and retained evidence.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should deployment administration change control and validation support produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
FDA's CSA record keeps assurance tied to intended use and process risk — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
FDA's data-integrity record keeps metadata and review in the laboratory system map — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
MHRA's current page points GLP readers to the later OECD data-integrity advisory — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
SiLA 2 standardizes an interface model—not laboratory workflow fitness — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
LabVantage's current portfolio shows LIMS, ELN, LES, and SDMS convergence without erasing the boundaries — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
Waters' current Empower record keeps CDS release and lifecycle questions visible — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.